1. Home
  2. LAW vs NGNE Comparison

LAW vs NGNE Comparison

Compare LAW & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$4.16

Market Cap

259.6M

Sector

Technology

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$19.61

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
NGNE
Founded
2013
2003
Country
United States
United States
Employees
577
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.6M
327.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LAW
NGNE
Price
$4.16
$19.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$8.00
$60.13
AVG Volume (30 Days)
484.5K
175.0K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
N/A
EPS
N/A
N/A
Revenue
$156,849,000.00
$925,000.00
Revenue This Year
$11.23
N/A
Revenue Next Year
$10.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.29
N/A
52 Week Low
$2.45
$6.88
52 Week High
$9.11
$37.27

Technical Indicators

Market Signals
Indicator
LAW
NGNE
Relative Strength Index (RSI) 47.77 45.74
Support Level $3.92 $19.44
Resistance Level $4.61 $21.03
Average True Range (ATR) 0.27 1.74
MACD 0.07 -0.47
Stochastic Oscillator 22.83 17.85

Price Performance

Historical Comparison
LAW
NGNE

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: